The startup develops optimized CRISPR guide RNA and edited cells for the cell biology and gene therapy research markets, offering products such as CRISPR reagents and gene knockout kits. Their solutions enable researchers to perform genome engineering more efficiently and reliably, facilitating advancements in genetic research and therapeutic applications.
Funding
$20M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Generating CRISPR-edited cell lines with high efficiency and reliability is time-consuming and requires specialized expertise, often delaying research and increasing costs. Traditional methods involve extensive optimization and can yield inconsistent results, hindering scientific progress.
Solution
EditCo Bio provides optimized CRISPR reagents and engineered cell lines, streamlining genome editing for cell biology and gene therapy research. The company leverages a high-throughput cell editing platform and multi-guide RNA designs to deliver efficient and consistent gene knockouts and knock-ins. EditCo offers a range of products, including gene knockout kits, arrayed gRNA libraries, immortalized cells, iPS cells, and primary cells, enabling researchers to accelerate their discoveries. Their XDel CRISPR technology improves editing accuracy and minimizes off-target effects, ensuring reliable results for various applications, including disease modeling, drug target identification, and cell and gene therapy development.
Target Audience
EditCo's primary customers are researchers in cell biology, gene therapy, drug discovery, and related fields, as well as pharmaceutical and biotechnology companies seeking to accelerate their research and development efforts.
Features
- XDel CRISPR technology utilizing multi-guide RNA for high on-target editing efficiency and minimal off-target effects
- Gene knockout kits with a unique multi-guide RNA strategy for efficient and consistent knockouts in human and mouse cell lines
- Arrayed CRISPR sgRNA libraries for high-throughput screening with guaranteed editing efficiency
- Custom-engineered immortalized, iPS, and primary cells with knockout and knock-in capabilities
- Automated cell line editing process for consistent performance and scalability
- Comprehensive QC reports including mycoplasma testing, passage number, and sequencing analysis
- Option for EditCo-supplied or customer-supplied cell lines
- ICE CRISPR analysis tool for evaluating editing efficiency